cardiotomskСибирский журнал клинической и экспериментальной медициныSiberian Journal of Clinical and Experimental Medicine2713-29272713-265XTSU publishing10.29001/2073-8552-2019-34-4-24-38cardiotomsk-860Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESНовые тренды и вызовы популяционной кардиологииEmerging trends and challenges of population-based cardiologyhttps://orcid.org/0000-0003-1106-0730АнфиногеноваЯ. Д.AnfinogenovaYa. J.

Анфиногенова Яна Джоновна - доктор медицинских наук, ведущий научный сотрудник, отделение популяционной кардиологии.

634012, Томск, ул. Киевская, 111а

Yana J. Anfinogenova - Dr. Sci. (Med.), Leading Research Scientist, Department of Cardiovascular Epidemiology.

111a, Kievskaya str., 634012, Tomsk

cardio.intl@gmail.comhttps://orcid.org/0000-0003-1063-7382ТрубачеваИ. А.TrubachevaI. A.

Трубачева Ирина Анатольевна - доктор медицинских наук, заведующий отделением популяционной кардиологии.

634012, Томск, ул. Киевская, 111а

Irina A. Trubacheva - M.D., Dr. Sci. (Med.), Head of the Department of Cardiovascular Epidemiology.

111a, Kievskaya str., 634012, Tomsk

tia@cardio-tomsk.ruhttps://orcid.org/0000-0002-9265-708XСеребряковаВ. Н.SerebryakovaV. N.

Серебрякова Виктория Николаевна - кандидат медицинских наук, заведующий лабораторией эпидемиологии сердечно-сосудистых заболеваний, высокотехнологичных вмешательств и телемедицины.

634012, Томск, ул. Киевская, 111а

Victoria N. Serebryakova - M.D., Cand. Sci. (Med.), Head of the Laboratory of Cardiovascular Epidemiology, High-Tech Medical Care, andTelemedicine.

111a, Kievskaya str., 634012, Tomsk

vsk75@yandex.ruhttps://orcid.org/0000-0002-9050-4493ПоповС. В.PopovS. V.

Попов Сергей Валентинович - доктор медицинских наук, профессор, академик РАН, директор.

634012, Томск, ул. Киевская, 111а

Sergey V. Popov - M.D., Dr. Sci. (Med.), Professor, Full Member of the Russian Academy of Sciences, Director.

111a, Kievskaya str., 634012, Tomsk

psv@cardio-tomsk.ruНаучно-исследовательский институт кардиологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation2019230120203442438Copyright © Анфиногенова Я.Д., Трубачева И.А., Серебрякова В.Н., Попов С.В., 20202020Анфиногенова Я.Д., Трубачева И.А., Серебрякова В.Н., Попов С.В.Anfinogenova Y.J., Trubacheva I.A., Serebryakova V.N., Popov S.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.sibjcem.ru/jour/article/view/860

Целью статьи является обзор зарубежной литературы относительно современных трендов и вызовов в области эпидемиологии сердечно-сосудистых заболеваний (ССЗ), включая появление новых факторов риска. Рассмотрено трансформирующее влияние омиксных технологий на эпидемиологию, сильные и слабые стороны метаэпидемиологии, а также роль мобильных технологий и электронных медицинских карт в укреплении здоровья населения. Отмечена важность преемственности между результатами эпидемиологических исследований и программами, ориентированными на улучшение здоровья местного населения. Авторы делают вывод, что изменение образа жизни людей в индустриальном обществе, глобализация, процессы миграции, бурное развитие технологий и промышленности сопровождаются трансформацией старых и появлением новых факторов риска ССЗ, требующих последовательного изучения и контроля. Революционные изменения в области биомедицинских технологий и эпидемиологических методов находят отражение в расширении международной терминологии. Учитывая, что новые термины рождаются на стыке трансформирующих направлений науки, авторы считают необходимым обновление и расширение российской терминологии в области эпидемиологии и смежных дисциплин наряду с внедрением новых биомедицинских подходов.

This article aims to review international literature on the current trends and challenges of cardiovascular epidemiology, including the emergence of new risk factors. The transformative impact of omics technologies on epidemiology, advantages and limitations of meta-epidemiology, as well as the role of mobile technologies and electronic medical records in maintaining and improving the cardiovascular health of the population are reviewed. Emphasis is given to the importance of continuity between the results acquired in the epidemiological studies and the programs aimed at the improvement of community health. The authors conclude that critical events make a significant impact on cardiovascular health. These events include changes in the lifestyle of people living in the industrial society, globalization, migration processes, and explosive development of new technologies and industries. Since these changes occur in parallel to the transformation of existing and emergence of new cardiovascular risk factors, then continuous research and control measures are required. Revolutionary changes in the field of biomedical technologies and advances in the epidemiological methodology translate into expanding the international terminology. New terms are continuously emerging at the junction of transforming areas of research. Therefore, along with the implementation of new biomedical technologies, the authors find it necessary to update and expand the vocabulary used in Russia in epidemiology and related disciplines.

сердечно-сосудистые заболеванияэпидемиологияомиксные технологииновые подходыфакторы рискаcardiovascular diseasesepidemiologyomics technologiesnew approachesrisk factorsReferencesVasan R.S., Benjamin E.J. The future of cardiovascular epidemiology. Circulation. 2016;133(25):2626-2633. DOI: 10.1161/CIRCULATIONA-HA.116.023528.Vasan R.S., Benjamin E.J. The future of cardiovascular epidemiology. Circulation. 2016;133(25):2626-2633. DOI: 10.1161/CIRCULATIONA-HA.116.023528.Manrai A.K., Ioannidis J.P.A., Patel C.J. Signals among signals: prioritizing nongenetic associations in massive data sets. American Journal of Epidemiology. 2019;188(5):846-850. DOI: 10.1093/aje/kwz031.Manrai A.K., Ioannidis J.P.A., Patel C.J. Signals among signals: prioritizing nongenetic associations in massive data sets. American Journal of Epidemiology. 2019;188(5):846-850. DOI: 10.1093/aje/kwz031.Epimonitor. The Voice of Epidemiology. Outgoing SER President Sees “Gross Failure" to improve population health and calls for a more “Consequential Epidemiology". Accessed on July 03, 2019. https://www.epimonitor.net/Consequential_Epidemiology.htm.Epimonitor. The Voice of Epidemiology. Outgoing SER President Sees “Gross Failure" to improve population health and calls for a more “Consequential Epidemiology". Accessed on July 03, 2019. https://www.epimonitor.net/Consequential_Epidemiology.htm.Galea S. An argument for a consequential epidemiology. American Journal of Epidemiology. 2013;178(8):1185-1191. DOI: 10.1093/aje/kwt172.Galea S. An argument for a consequential epidemiology. American Journal of Epidemiology. 2013;178(8):1185-1191. DOI: 10.1093/aje/kwt172.Keyes K., Galea S. What matters most: quantifying an epidemiology of consequence. Annals of Epidemiology 2015;25(5):305-311. DOI: 10.1016/j.annepidem.2015.01.016.Keyes K., Galea S. What matters most: quantifying an epidemiology of consequence. Annals of Epidemiology 2015;25(5):305-311. DOI: 10.1016/j.annepidem.2015.01.016.Khoury M.J., Gwinn M., Ioannidis J.P. The emergence of translational epidemiology: from scientific discovery to population health impact. American Journal of Epidemiology. 2010;172(5):517-524. DOI: 10.1093/aje/kwq211.Khoury M.J., Gwinn M., Ioannidis J.P. The emergence of translational epidemiology: from scientific discovery to population health impact. American Journal of Epidemiology. 2010;172(5):517-524. DOI: 10.1093/aje/kwq211.Pang H., Jia W., Hu Z. Emerging applications of metabolomics in clinical pharmacology. Clinical Pharmacology&Therapeutics. 2019;106(3):544-556. DOI: 10.1002/cpt.1538.Pang H., Jia W., Hu Z. Emerging applications of metabolomics in clinical pharmacology. Clinical Pharmacology&Therapeutics. 2019;106(3):544-556. DOI: 10.1002/cpt.1538.Ge X., Zheng L., Zhuang R., Yu P., Xu Z., Liu G. et al. The gut microbial metabolite trimethylamine N-oxide and hypertension risk: a systematic review and dose-response meta-analysis. Advances in Nutrition. 2019; Jul. 3. DOI: 10.1093/advances/nmz064. Interventionist approaches to epidemiology.Ge X., Zheng L., Zhuang R., Yu P., Xu Z., Liu G. et al. The gut microbial metabolite trimethylamine N-oxide and hypertension risk: a systematic review and dose-response meta-analysis. Advances in Nutrition. 2019; Jul. 3. DOI: 10.1093/advances/nmz064. Interventionist approaches to epidemiology.Schiattarella G.G., Sannino A., Toscano E., Giugliano G., Gargiulo G., Franzone A. et al. Gut microbe-generated metabolite trimethyl-amine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur. Heart J. 2017;38(39):2948-2956. DOI: 10.1093/eurheartj/ehx342.Schiattarella G.G., Sannino A., Toscano E., Giugliano G., Gargiulo G., Franzone A. et al. Gut microbe-generated metabolite trimethyl-amine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur. Heart J. 2017;38(39):2948-2956. DOI: 10.1093/eurheartj/ehx342.Zhuang R., Ge X., Han L., Yu P., Gong X., Meng Q. et al. Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: A systematic review and dose-response meta-analysis. Obes. Rev. 2019;20(6):883-894. DOI: 10.1111/obr.12843.Zhuang R., Ge X., Han L., Yu P., Gong X., Meng Q. et al. Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: A systematic review and dose-response meta-analysis. Obes. Rev. 2019;20(6):883-894. DOI: 10.1111/obr.12843.Tang W.H., Wang Z., Kennedy D.J., Wu Y, Buffa J.A., Agatisa-Boyle B. et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 2015;116(3):448-455. DOI: 10.1161/CIRCRESAHA.116.305360.Tang W.H., Wang Z., Kennedy D.J., Wu Y, Buffa J.A., Agatisa-Boyle B. et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ. Res. 2015;116(3):448-455. DOI: 10.1161/CIRCRESAHA.116.305360.Halmos T., Suba I. Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases. Orv. Hetil. 2017;158(52):2051-2061. DOI: 10.1556/650.2017.30936.Halmos T., Suba I. Non-alcoholic fatty liver disease, as a component of the metabolic syndrome, and its causal correlations with other extrahepatic diseases. Orv. Hetil. 2017;158(52):2051-2061. DOI: 10.1556/650.2017.30936.Naylor C.D. Meta-analysis and the meta-epidemiology of clinical research. BMJ. 1997;315(7109):617-619.Naylor C.D. Meta-analysis and the meta-epidemiology of clinical research. BMJ. 1997;315(7109):617-619.Murad M.H., Wang Z. Guidelines for reporting meta-epidemiological methodology research. BMJ. Evidence-Based Medicine. 2017;22(4):139-142. DOI: 10.1136/ebmed-2017-110713.Murad M.H., Wang Z. Guidelines for reporting meta-epidemiological methodology research. BMJ. Evidence-Based Medicine. 2017;22(4):139-142. DOI: 10.1136/ebmed-2017-110713.Bae J.M. Meta-epidemiology. Epidemiol. Health. 2014;36:e2014019. DOI: 10.4178/epih/e2014019.Bae J.M. Meta-epidemiology. Epidemiol. Health. 2014;36:e2014019. DOI: 10.4178/epih/e2014019.Trinquart L., Dechartres A., Ravaud P. Commentary: Meta-epidemiology, meta-meta-epidemiology or network meta-epidemiology? Int. J. Epidemiol. 2013;42(4):1131-1133. DOI: 10.1093/ije/dyt137.Trinquart L., Dechartres A., Ravaud P. Commentary: Meta-epidemiology, meta-meta-epidemiology or network meta-epidemiology? Int. J. Epidemiol. 2013;42(4):1131-1133. DOI: 10.1093/ije/dyt137.Fortunato S., Bergstrom C.T., Borner K., Evans J.A., Helbing D., Milo-jevic S. et al. Science of science. Science. 2018;359(6379): eaao0185. DOI: 10.1126/science.aao0185.Fortunato S., Bergstrom C.T., Borner K., Evans J.A., Helbing D., Milo-jevic S. et al. Science of science. Science. 2018;359(6379): eaao0185. DOI: 10.1126/science.aao0185.Salanti G., Higgins J.P., Ades A.E., Ioannidis J.P. Evaluation of networks of randomized trials. Stat. Methods Med. Res. 2007;17(3):279-301. DOI: 10.1177/0962280207080643.Salanti G., Higgins J.P., Ades A.E., Ioannidis J.P. Evaluation of networks of randomized trials. Stat. Methods Med. Res. 2007;17(3):279-301. DOI: 10.1177/0962280207080643.Damen J.A.A.G., Debray T.P.A., Pajouheshnia R., Reitsma J.B., Scholten R.J.P.M., Moons K.G.M. et al. Empirical evidence of the impact of study characteristics on the performance of prediction models: a meta-epidemiological study. BMJ Open. 2019;9(4):e026160. DOI: 10.1136/bm-jopen-2018-026160.Damen J.A.A.G., Debray T.P.A., Pajouheshnia R., Reitsma J.B., Scholten R.J.P.M., Moons K.G.M. et al. Empirical evidence of the impact of study characteristics on the performance of prediction models: a meta-epidemiological study. BMJ Open. 2019;9(4):e026160. DOI: 10.1136/bm-jopen-2018-026160.Held U., Kessels A., Garcia Aymerich J., Basagana X., Ter Riet G., Moons K.G. et al. Methods for handling missing variables in risk prediction models. American Journal of Epidemiology. 2016;184(7):545-551. DOI: 10.1093/aje/kwv346.Held U., Kessels A., Garcia Aymerich J., Basagana X., Ter Riet G., Moons K.G. et al. Methods for handling missing variables in risk prediction models. American Journal of Epidemiology. 2016;184(7):545-551. DOI: 10.1093/aje/kwv346.Janssen K.J., Vergouwe Y, Donders A.R., Harrell F.E. Jr., Chen Q., Grob-bee D.E. et al. Dealing with missing predictor values when applying clinical prediction models. Clin. Chem. 2009;55(5):994-1001. DOI: 10.1373/clinchem.2008.115345.Janssen K.J., Vergouwe Y, Donders A.R., Harrell F.E. Jr., Chen Q., Grob-bee D.E. et al. Dealing with missing predictor values when applying clinical prediction models. Clin. Chem. 2009;55(5):994-1001. DOI: 10.1373/clinchem.2008.115345.Moons K.G., Altman D.G., Reitsma J.B., Ioannidis J.P., Macaskill P., Stey-erberg E.W. et al. Transparent reporting of a multivariable prediction model for Individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann. Intern. Med. 2015;162(1):W1-73. DOI: 10.7326/M14-0698.Moons K.G., Altman D.G., Reitsma J.B., Ioannidis J.P., Macaskill P., Stey-erberg E.W. et al. Transparent reporting of a multivariable prediction model for Individual prognosis or diagnosis (TRIPOD): explanation and elaboration. Ann. Intern. Med. 2015;162(1):W1-73. DOI: 10.7326/M14-0698.Storz-Pfennig P. Potentially unnecessary and wasteful clinical trial research detected in cumulative meta-epidemiological and trial sequential analysis. J. Clin. Epidemiol. 2017;82:61-70. DOI: 10.1016/j. jclinepi.2016.11.003.Storz-Pfennig P. Potentially unnecessary and wasteful clinical trial research detected in cumulative meta-epidemiological and trial sequential analysis. J. Clin. Epidemiol. 2017;82:61-70. DOI: 10.1016/j. jclinepi.2016.11.003.Antman E.M., Loscalzo J. Precision medicine in cardiology. Nat. Rev. Cardiol. 2016;13(10):591-602. DOI: 10.1038/nrcardio.2016.101.Antman E.M., Loscalzo J. Precision medicine in cardiology. Nat. Rev. Cardiol. 2016;13(10):591-602. DOI: 10.1038/nrcardio.2016.101.McManus D.D., Trinquart L., Benjamin E.J., Manders E.S., Fusco K., Jung L.S. et al. Design and Preliminary Findings From a New Electronic Cohort Embedded in the Framingham Heart Study. J. Med. Internet. Res. 2019;21(3):e12143. DOI: 10.2196/12143.McManus D.D., Trinquart L., Benjamin E.J., Manders E.S., Fusco K., Jung L.S. et al. Design and Preliminary Findings From a New Electronic Cohort Embedded in the Framingham Heart Study. J. Med. Internet. Res. 2019;21(3):e12143. DOI: 10.2196/12143.Vineis P., Chadeau-Hyam M., Gmuender H., Gulliver J., Herceg Z., Kleinjans J. et al. The exposome in practice: Design of the EXPOsOM-ICS project. Int. J. Hyg. Environ. Health. 2017;220(2):142-151. DOI: 10.1016/j.ijheh.2016.08.001.Vineis P., Chadeau-Hyam M., Gmuender H., Gulliver J., Herceg Z., Kleinjans J. et al. The exposome in practice: Design of the EXPOsOM-ICS project. Int. J. Hyg. Environ. Health. 2017;220(2):142-151. DOI: 10.1016/j.ijheh.2016.08.001.Zhu Y, Gu X., Xu C. Effectiveness of telemedicine systems for adults with heart failure: a meta-analysis of randomized controlled trials. Heart Fail. Rev. 2019;May24. DOI: 10.1007/s10741-019-09801-5.Zhu Y, Gu X., Xu C. Effectiveness of telemedicine systems for adults with heart failure: a meta-analysis of randomized controlled trials. Heart Fail. Rev. 2019;May24. DOI: 10.1007/s10741-019-09801-5.Omboni S., Posokhov I., Parati G., Rogoza A., Kotovskaya Y, Arystan A. et al. Ambulatory blood pressure and arterial stiffness web-based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive patients) Registry. J. Clin. Hypertens. (Greenwich). 2019;21(8):1155-1168. DOI: 10.1111/jch.13623.Omboni S., Posokhov I., Parati G., Rogoza A., Kotovskaya Y, Arystan A. et al. Ambulatory blood pressure and arterial stiffness web-based telemonitoring in patients at cardiovascular risk. First results of the VASOTENS (Vascular health ASsessment Of The hypertENSive patients) Registry. J. Clin. Hypertens. (Greenwich). 2019;21(8):1155-1168. DOI: 10.1111/jch.13623.Fox C.S., Hwang S.J., Nieto K., Valentino M., Mutalik K., Massaro J.M. et al. Digital Connectedness in the Framingham Heart Study. J. Am. Heart Assoc. 2016;5(4):e003193. DOI: 10.1161/JAHA.116.003193.Fox C.S., Hwang S.J., Nieto K., Valentino M., Mutalik K., Massaro J.M. et al. Digital Connectedness in the Framingham Heart Study. J. Am. Heart Assoc. 2016;5(4):e003193. DOI: 10.1161/JAHA.116.003193.Schofield P., Shaw T., Pascoe M. Toward comprehensive patient-centric care by integrating digital health technology with direct clinical contact in Australia. J. Med. Internet Res. 2019;21(6):e12382. DOI: 10.2196/12382.Schofield P., Shaw T., Pascoe M. Toward comprehensive patient-centric care by integrating digital health technology with direct clinical contact in Australia. J. Med. Internet Res. 2019;21(6):e12382. DOI: 10.2196/12382.Treskes R.W., Wildbergh T.X., Schalij M.J., Scherptong R.W.C. Expectations and perceived barriers to widespread implementation of e-Health in cardiology practice: Results from a national survey in the Netherlands. Neth. Heart J. 2019;27(1):18-23. DOI: 10.1007/s12471-018-1199-9.Treskes R.W., Wildbergh T.X., Schalij M.J., Scherptong R.W.C. Expectations and perceived barriers to widespread implementation of e-Health in cardiology practice: Results from a national survey in the Netherlands. Neth. Heart J. 2019;27(1):18-23. DOI: 10.1007/s12471-018-1199-9.Hemingway H., Asselbergs F.W., Danesh J., Dobson R., Maniadakis N., Maggioni A. et al. Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. Eur. Heart J. 2018;39(16):1481-1495. DOI: 10.1093/eurheartj/ehx487.Hemingway H., Asselbergs F.W., Danesh J., Dobson R., Maniadakis N., Maggioni A. et al. Big data from electronic health records for early and late translational cardiovascular research: challenges and potential. Eur. Heart J. 2018;39(16):1481-1495. DOI: 10.1093/eurheartj/ehx487.Puska P. From Framingham to North Karelia: from descriptive epidemiology to public health action. Prog. Cardiovasc. Dis. 2010;53(1):15-20. DOI: 10.1016/j.pcad.2010.01.003.Puska P. From Framingham to North Karelia: from descriptive epidemiology to public health action. Prog. Cardiovasc. Dis. 2010;53(1):15-20. DOI: 10.1016/j.pcad.2010.01.003.Pearson T.A., Palaniappan L.P., Artinian N.T., Carnethon M.R., Criqui M.H., Daniels S.R. et al. American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers. Circulation. 2013;127(16):1730-1753. DOI: 10.1161/CIR.0b013e31828f8a94.Pearson T.A., Palaniappan L.P., Artinian N.T., Carnethon M.R., Criqui M.H., Daniels S.R. et al. American Heart Association Guide for Improving Cardiovascular Health at the Community Level, 2013 update: a scientific statement for public health practitioners, healthcare providers, and health policy makers. Circulation. 2013;127(16):1730-1753. DOI: 10.1161/CIR.0b013e31828f8a94.Andersson C., Johnson A.D., Benjamin E.J., Levy D., Vasan R.S. 70-year legacy of the Framingham Heart Study. Nat. Rev. Cardiol. 2019;May 7. DOI: 10.1038/s41569-019-0202-5.Andersson C., Johnson A.D., Benjamin E.J., Levy D., Vasan R.S. 70-year legacy of the Framingham Heart Study. Nat. Rev. Cardiol. 2019;May 7. DOI: 10.1038/s41569-019-0202-5.Muhlack D.C., Hoppe L.K., Weberpals J., Brenner H., Schottker B. The Association of Potentially Inappropriate Medication at Older Age with Cardiovascular Events and Overall Mortality: A Systematic Review and Meta-Analysis of Cohort Studies. J. Am. Med. Dir. Assoc. 2017;18(3):211-220. DOI: 10.1016/j.jamda.2016.11.025.Muhlack D.C., Hoppe L.K., Weberpals J., Brenner H., Schottker B. The Association of Potentially Inappropriate Medication at Older Age with Cardiovascular Events and Overall Mortality: A Systematic Review and Meta-Analysis of Cohort Studies. J. Am. Med. Dir. Assoc. 2017;18(3):211-220. DOI: 10.1016/j.jamda.2016.11.025.Grina D., Briedis V. The use of potentially inappropriate medications among the Lithuanian elderly according to Beers and EU(7)-PIM list -a nationwide cross-sectional study on reimbursement claims data. J. Clin. Pharm. Ther. 2017;42(2):195-200. DOI: 10.1111/jcpt.12494.Grina D., Briedis V. The use of potentially inappropriate medications among the Lithuanian elderly according to Beers and EU(7)-PIM list -a nationwide cross-sectional study on reimbursement claims data. J. Clin. Pharm. Ther. 2017;42(2):195-200. DOI: 10.1111/jcpt.12494.Beers M.H., Ouslander J.G., Rollingher I., Reuben D.B., Brooks J., Beck J.C. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch. Intern. Med. 1991;151:1825-1832. DOI: 10.1001/archinte.1991.00400090107019.Beers M.H., Ouslander J.G., Rollingher I., Reuben D.B., Brooks J., Beck J.C. Explicit criteria for determining inappropriate medication use in nursing home residents. UCLA Division of Geriatric Medicine. Arch. Intern. Med. 1991;151:1825-1832. DOI: 10.1001/archinte.1991.00400090107019.Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch. Intern. Med. 1997;157(14):1531-1536. DOI: 10.1001/archinte.1997.00440350031003.Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch. Intern. Med. 1997;157(14):1531-1536. DOI: 10.1001/archinte.1997.00440350031003.The National Committee for Quality Assurance. HEDIS 2016 final NDC lists - Use of high-risk medications in the elderly (DAE). Accessed August 1, 2016. http://www.ncqa.org/hedis-quality-measurement/hedis-mea-sures/hedis-2016/hedis-2016-ndclicense/hedis-2016-final-ndc-lists.The National Committee for Quality Assurance. HEDIS 2016 final NDC lists - Use of high-risk medications in the elderly (DAE). Accessed August 1, 2016. http://www.ncqa.org/hedis-quality-measurement/hedis-mea-sures/hedis-2016/hedis-2016-ndclicense/hedis-2016-final-ndc-lists.Stolar M.H. Drug use review: Operational definitions. American Journal Hospital Pharmacy. 1978;35(1):76-78. DOI: 10.1093/ajhp/35.1.76.Stolar M.H. Drug use review: Operational definitions. American Journal Hospital Pharmacy. 1978;35(1):76-78. DOI: 10.1093/ajhp/35.1.76.Fastbom J., Johnell K. National indicators for quality of drug therapy in older persons: The Swedish experience from the first 10 years. Drugs Aging. 2015;32(3):189-199. DOI: 10.1007/s40266-015-0242-4.Fastbom J., Johnell K. National indicators for quality of drug therapy in older persons: The Swedish experience from the first 10 years. Drugs Aging. 2015;32(3):189-199. DOI: 10.1007/s40266-015-0242-4.Fick D.M., Cooper J.W., Wade W.E., Waller J.L., Maclean J.R., Beers M.H. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch. Intern. Med. 2003;163(22):2716-2724. DOI: 10.1001/archinte.163.22.2716.Fick D.M., Cooper J.W., Wade W.E., Waller J.L., Maclean J.R., Beers M.H. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch. Intern. Med. 2003;163(22):2716-2724. DOI: 10.1001/archinte.163.22.2716.McLeod PJ., Huang A.R., Tamblyn R.M., Gayton D.C. Defining inappropriate practices in prescribing for elderly people: A national consensus panel. CMAJ. 1997;156(3):385-391.McLeod PJ., Huang A.R., Tamblyn R.M., Gayton D.C. Defining inappropriate practices in prescribing for elderly people: A national consensus panel. CMAJ. 1997;156(3):385-391.Elliott R.A. Problems with medication use in the elderly: An Australian perspective. J. Pharm. Pract. Res. 2006;36(1):58-66. DOI: 10.1002/j.2055-2335.2006.tb00889.x.Elliott R.A. Problems with medication use in the elderly: An Australian perspective. J. Pharm. Pract. Res. 2006;36(1):58-66. DOI: 10.1002/j.2055-2335.2006.tb00889.x.Roughead E.E., Anderson B., Gilbert A.L. Potentially inappropriate prescribing among Australian veterans and war widows/wid-owers. Intern. Med. J. 2007;37(6):402-405. DOI: 10.1111/j.1445-5994.2007.01316.x.Roughead E.E., Anderson B., Gilbert A.L. Potentially inappropriate prescribing among Australian veterans and war widows/wid-owers. Intern. Med. J. 2007;37(6):402-405. DOI: 10.1111/j.1445-5994.2007.01316.x.American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 2012;60(4):616-631. DOI: 10.1111/j.1532-5415.2012.03923.x.American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 2012;60(4):616-631. DOI: 10.1111/j.1532-5415.2012.03923.x.American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 2015;63(11):2227-2246. DOI: 10.1111/jgs.13702.American Geriatrics Society 2015 Beers Criteria Update Expert Panel. American Geriatrics Society 2015 Updated Beers criteria for potentially inappropriate medication use in older adults. J. Am. Geriatr. Soc. 2015;63(11):2227-2246. DOI: 10.1111/jgs.13702.Renom-Guiteras A., Meyer G., Th'rmann P.A. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur. J. Clin. Pharmacol. 2015;71(7):861-875. DOI: 10.1007/s00228-015-1860-9.Renom-Guiteras A., Meyer G., Th'rmann P.A. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur. J. Clin. Pharmacol. 2015;71(7):861-875. DOI: 10.1007/s00228-015-1860-9.Ivanova I., Elseviers M., Wettermark B., Schmidt Mende K., Vander Stichele R., Christiaens T. Electronic assessment of cardiovascular potentially inappropriate medications in an administrative population database. BCPT. 2019;124(1):62-73. DOI: 10.1111/bcpt.13095.Ivanova I., Elseviers M., Wettermark B., Schmidt Mende K., Vander Stichele R., Christiaens T. Electronic assessment of cardiovascular potentially inappropriate medications in an administrative population database. BCPT. 2019;124(1):62-73. DOI: 10.1111/bcpt.13095.Jin K., Gullick J., Neubeck L., Koo F., Ding D. Acculturation is associated with higher prevalence of cardiovascular disease risk-factors among Chinese immigrants in Australia: Evidence from a large population-based cohort. Eur. JPrev. Cardiol. 2017;24(18):2000-2008. DOI: 10.1177/2047487317736828.Jin K., Gullick J., Neubeck L., Koo F., Ding D. Acculturation is associated with higher prevalence of cardiovascular disease risk-factors among Chinese immigrants in Australia: Evidence from a large population-based cohort. Eur. JPrev. Cardiol. 2017;24(18):2000-2008. DOI: 10.1177/2047487317736828.Guo S., Lucas R.M., Joshy G., Banks E. Cardiovascular disease risk factor profiles of 263,356 older Australians according to region of birth and acculturation, with a focus on migrants born in Asia. PLoS One. 2015;10(2):e0115627. DOI: 10.1371/journal.pone.0115627.Guo S., Lucas R.M., Joshy G., Banks E. Cardiovascular disease risk factor profiles of 263,356 older Australians according to region of birth and acculturation, with a focus on migrants born in Asia. PLoS One. 2015;10(2):e0115627. DOI: 10.1371/journal.pone.0115627.Tavares L., Calhau C., Polonia J. Assessment of cardiovascular risk and social framework of Cape Verdean university students studying in Portugal. Rev. Port. Cardiol. 2018;37(7):577-582. DOI: 10.1016/j.repc.2017.09.027.Tavares L., Calhau C., Polonia J. Assessment of cardiovascular risk and social framework of Cape Verdean university students studying in Portugal. Rev. Port. Cardiol. 2018;37(7):577-582. DOI: 10.1016/j.repc.2017.09.027.Choi M., Mesa-Frias M., Nuesch E., Hargreaves J., Prieto-Merino D., Bowling A. et al. Social capital, mortality, cardiovascular events and cancer: a systematic review of prospective studies. Int. J. Epidemiol. 2014;43(6):1895-1920. DOI: 10.1093/ije/dyu212.Choi M., Mesa-Frias M., Nuesch E., Hargreaves J., Prieto-Merino D., Bowling A. et al. Social capital, mortality, cardiovascular events and cancer: a systematic review of prospective studies. Int. J. Epidemiol. 2014;43(6):1895-1920. DOI: 10.1093/ije/dyu212.Hamad R., Nguyen T.T., Bhattacharya J., Glymour M.M., Rehkopf D.H. Educational attainment and cardiovascular disease in the United States: A quasi-experimental instrumental variables analysis. PLoS Med. 2019;16(6):e1002834. DOI: 10.1371/journal.pmed.1002834.Hamad R., Nguyen T.T., Bhattacharya J., Glymour M.M., Rehkopf D.H. Educational attainment and cardiovascular disease in the United States: A quasi-experimental instrumental variables analysis. PLoS Med. 2019;16(6):e1002834. DOI: 10.1371/journal.pmed.1002834.Braveman P., Gottlieb L. The social determinants of health: it's time to consider the causes of the causes. Public Health Rep. 2014;129(2):19-31. DOI: 10.1177/00333549141291S206.Braveman P., Gottlieb L. The social determinants of health: it's time to consider the causes of the causes. Public Health Rep. 2014;129(2):19-31. DOI: 10.1177/00333549141291S206.Currie D.J., Smith C., Jagals P. The application of system dynamics modelling to environmental health decision-making and policy - a scoping review. BMC Public Health. 2018;18(1):402. DOI: 10.1186/s12889-018-5318-8.Currie D.J., Smith C., Jagals P. The application of system dynamics modelling to environmental health decision-making and policy - a scoping review. BMC Public Health. 2018;18(1):402. DOI: 10.1186/s12889-018-5318-8.Alderwick H., Gottlieb L.M. Meanings and misunderstandings: a social determinants of health lexicon for health care systems. Milbank Quarterly. 2019;97(2):407-419. DOI: 10.1111/1468-0009.12390.Alderwick H., Gottlieb L.M. Meanings and misunderstandings: a social determinants of health lexicon for health care systems. Milbank Quarterly. 2019;97(2):407-419. DOI: 10.1111/1468-0009.12390.

The authors declare that there are no conflicts of interest present.